Specifically, the upregulation of SMAD1, SMAD3, SMAD4, BMP2, MAPK1, and SKIL—driven by promoter hypomethylation and reduced expression of tumor-suppressive microRNAs—leads to enhanced activation of both canonical and non-canonical branches of TGF-β signaling. The gene discussed is BMP2; the disease is neoplasm.